Lancet

• Latest
• Best
• Search…

• Lancet · May 2022

  Letter

  Adverse pregnancy outcomes: biological essentialism versus embodied biology.

  no abstract available

  read more… or not…

• Lancet · May 2022

  Calls for independent evaluation of ACT-A welcomed.

  no abstract available

  read on… or not…

• Lancet · May 2022

  Randomized Controlled Trial

  Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.

  Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease. ⋯ AbbVie.

  expand abstract… or not…

• Lancet · May 2022

  Effective post-pandemic governance must focus on shared challenges.

  no abstract available

  expand abstract… or not…

• Lancet · May 2022

  Letter

  Violence against health-care workers in the Philippines.

  no abstract available

  read more… or just mark as read…